Mr. Joe Todisco is Chief Executive Officer of CorMedix and a member of the Board of Directors. Prior to joining CorMedix, he spent eleven years in various roles at Amneal Pharmaceuticals, most recently as Chief Commercial Officer of Amneal Specialty, as well as Senior Vice President Corporate Development & International Operations. He was also co-founder and formerly chief executive of Gemini Laboratories LLC, a specialty pharmaceutical company that was subsequently acquired by Amneal. Prior to joining Amneal, Joe spent more than five years leading Ranbaxy Pharmaceutical’s North American Commercial Strategy and Business Development, and prior to Ranbaxy, held various leadership roles with Par Pharmaceuticals. Joe holds a bachelor’s degree in Economics from Georgetown University and an M.B.A. from Fordham Graduate School of Business.
Susan joined Melinta Therapeutics in 2016 and was an integral part of Melinta’s leadership team, serving as CFO from April 2021 until August 2025, at which time she assumed the role of CFO for CorMedix in connection with the merger of the companies. With more than 25 years of experience in both public and private companies, Susan brings deep experience in strategic planning, risk management, and financial operations. Before joining Melinta, she served in leadership positions within corporate controllership and financial reporting at Textura Corporation (now Oracle), Orbitz Worldwide (now Expedia), and PDL BioPharma and Facet Therapeutics (now Abbott), in which she played key roles in public offerings, mergers, acquisitions, and other strategic transactions. In April 2024, Susan was appointed to the Board of Directors and Audit Committee Chair for BiomX, a public, clinical-stage company pioneering phage cocktails to combat bacteria in chronic diseases. She holds a B.S. in Business Commerce, concentration in Accounting, from Santa Clara University and is a certified public accountant.
Liz Hurlburt serves as our EVP, Chief Operating Officer, overseeing Alliance Management, Clinical Development, Medical Affairs, Quality, Supply Chain and Technical Operations. She was most recently the EVP, Clinical Strategy and Operations for CorMedix. Over the past twenty years she has held several progressive management roles in clinical operations and strategic turnarounds, at Gemphire Therapeutics, Accelovance and starting Clinical Minds, LLC, a specialty consulting group. Liz has a passion balancing culture, engagement and company growth. Liz received her B.A. in Leadership and Organizational Management and a Master’s in Management and Leadership.
Beth Zelnick Kaufman was appointed as EVP, Chief Legal and Compliance Officer, and Corporate Secretary in December 2023. She leads the company’s legal and compliance activities. Prior to joining CorMedix, she most recently served as Chief Legal and Administrative Officer and Corporate Secretary of Akorn Pharmaceuticals, a specialty and generic pharmaceuticals company. Ms. Zelnick Kaufman also served as Chief Legal Officer of The Broad Institute of MIT & Harvard and in several roles at Amneal Pharmaceuticals, a publicly traded global generics, biosimilars, and branded pharmaceuticals company, including roles as Assistant General Counsel, Vice President, Legal Affairs, and Head of Government Affairs. Ms. Zelnick Kaufman holds a Juris Doctor degree from New York University Law School and a Bachelor of Arts degree from Amherst College.
Matt David was appointed Executive Vice President and Chief Business Officer in August 2025. Dr. David also served as CorMedix’s CFO from May 2020 to August 2025 and interim CEO from October 2021 to May 2022. He leads the company’s corporate development, capital markets, and investor relations activities. Prior to joining CorMedix, Dr. David was Head of Strategy at Ovid Therapeutics and spent the majority of his career in healthcare investment banking roles where he advised life sciences companies on a broad range of financing and strategic transactions. Earlier in his career, Dr. David spent time as a research analyst covering the pharma sector. Dr. David received his M.D. from NYU School of Medicine and his undergraduate degree from Dartmouth College.